Study: Pfizer Hemophilia Drug Reduces Bleeding Rates

story

MAY 2023

story last updated JAN 31

The Spin

Narrative A

This study's results are promising and could be the first step towards Pfizer's marstacimab revolutionizing treatment for patients with hemophilia A or B. These results suggests the drug could prevent excessive bleeds and reduce treatment burden through once-weekly, under-the-skin administration.

Pfizer

Narrative B

While the experimental therapy is undeniably innovative — as it reduces the amount of anticoagulation instead of addressing the factor deficiency — TFPI blockers in marstacimab can cause clotting episodes that do not usually show up in small studies. The medical community should not get too excited about this development too soon.

Investor's Business Daily